may begin human trials this week for two mRNA-based HIV vaccines, according to the National Institutes of Health’s clinical trial registry.
The study, in the Phase I stage, would measure the safety of the vaccine and collect information on whether the potential vaccine has an impact on HIV.The research would have to go to Phases II and III stages to collect the data on whether the vaccine is effective or not.
The HIV vaccine candidates have been determined to be safe to test on humans.Moderna is currently looking for 56 participants for the study between the ages of 18 and 50.
The trial is set to begin on August 19, ending in 2023.The potential vaccine is different than previous ones because the technology used is the same technology used.